MIRA INFORM
REPORT
|
Report Date : |
28.02.2011 |
IDENTIFICATION DETAILS
|
Correct Name : |
AL RAWAD PHARMA INDUSTRIES CO |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
August 2004 |
|
|
|
|
Com. Reg. No.: |
281, 10th Of |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceuticals and drugs |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 350,000 |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2010
|
Country Name |
Previous Rating (01.04.2010) |
Current Rating (30.06.2010) |
|
|
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SUMMARY
Company Name : AL RAWAD PHARMA INDUSTRIES CO
Also Known As : AL RAWAD PHARMA INC CO
Country of Origin :
Legal Form : Egyptian Joint Stock Company
Registration Date : August 2004
Commercial Registration Number : 281, 10th Of
Issued Capital : £E 8,000,000
Paid up Capital : £E 8,000,000
Total Workforce : 150
Activities : Manufacture of pharmaceuticals and drugs
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 350,000
Person Interviewed :
Sameh Mohamed Abdul Fattah Al
COMPANY NAME
AL RAWAD PHARMA INDUSTRIES CO
ALSO KNOWN AS
AL RAWAD PHARMA INC CO
company ADDRESS
Registered & Physical Address
Location :
Town : Zagazig
Country :
Telephone : (20-55) 2387040
/ 2387050
Facsimile : (20-55) 2387040
Email : alrawad_pharma@yahoo.com
Premises
Subject operates from
a medium sized suite of offices that are rented and located in the Suburban
Business Area of Zagazig.
Branch Office (s)
Location Description
·
Plot No. 146, Block B3 Factory
premises
Industrial Zone
10th
Of
Tel: (20-15) 375817
Fax: (20-15) 375823
·
Tel: (20-2)
26398448
Fax: (20-2)
26398448
Note: The company was
previously located at
KEY PRINCIPALS
Name Position
·
Dr Khalid Mohamed Abdul Fattah Al
·
Dr Hisham Mohamed Hussain Al Maghrabi Managing
Director
·
Dr Mohamed Othman Lofty Director
·
Sameh Mohamed Abdul Fattah Al
·
Dr Abdul
Zaher Hamed Director
·
Dr Khalid Al Najjar Business
Development Manager
·
Dr
Nabiha Balikini Production
Manager
·
Shrihan
Adel Administration
Executive
LEGAL FORM & OWNERS
Date of Establishment : August 2004
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 281, 10th Of
Authorised
Capital : £E 20,000,000
Issued Capital : £E
8,000,000
Paid up Capital : £E 8,000,000
Name of Shareholder
(s)
·
Dr Khalid Mohamed Abdul Fattah Al
·
Dr Hisham Mohamed Hussain Al Maghrabi
·
Dr Mohamed Othman Lofty
·
Sameh Mohamed Abdul Fattah Al
·
Dr
Abdul Zaher Hamed
OPERATIONS
Activities: Engaged in the manufacture of pharmaceuticals and drugs. Subject began manufacturing
activities at the start of 2009 and was previously marketing and distributing
pharmaceutical products.
Import
Countries:
Operating Trend: Steady
Subject has a
workforce of approximately 150 employees.
FINANCIAL DATA
Financial highlights
provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/10:
Total Sales £E
45,000,000
Local sources
consider subject’s financial condition to be Fair.
The above figures
were provided by Mr Sameh Mohamed Abdul Fattah
Al Akkad, Director
BANKERS
·
Faisal
Islamic Bank of
Tel: (20-2) 22753165
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
During the course of
this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk and the above credit figure is
within subject’s financial means.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.18 |
|
|
1 |
Rs.72.79 |
|
Euro |
1 |
Rs.62.15 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.